\
&
Contact us
\
&
Contact us
Published on | 2 years ago
ProgrammesThe results of the 2023 European Research Council (ERC) Synergy Grant call (call deadline 8 November 2022) were published. Synergy grant projects consist of minimum two tot maximum four Principal Investigators (PIs) and their teams that collaborate and pool knowledge, skills and resources to address ambitious research problems. In total 37 projects with 135 PIs received a Synergy grant including one researcher based at a Flemish host institution:
Kevin Verstrepen (Vlaams Instituut voor Biotechnologie (VIB)) is involved in the project “ EPIC - Unravelling the eukaryotic posttranscriptional regulatory”
More information on that project can be found in the interview with Kevin Verstrepen and the two collaborating PIs Julien Gagneur (Technische Universität München) and Vicente Pelechano (Karolinska Institutet) included in the news articles of the VIB and KU Leuven. In the ERCEA news articles the list of selected projects and several other examples of projects are highlighted.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
